HK Stock Market Move | INSILICO (03696) surged over 4% during trading and announced a research collaboration with South Korea's THPharm.

INSILICO (03696) rose over 4% during trading, and as of the time of writing, it is up 3%, priced at HKD 47.38, with a trading volume of HKD 259 million. In news, on August 13, INSILICO announced via its official WeChat account that the company has reached a research collaboration with THPharm, which focuses on drug development for metabolic diseases. This collaboration aims to establish a "reverse analysis" strategy for drug research and development based on biological AI: starting from the clearly defined efficacy data obtained during the preclinical phase of candidate drugs, it seeks to deduce potential indications, mechanisms of action, and biomarker systems for development, further expanding the application boundaries of existing candidate drug pipelines. Leveraging INSILICO's core biological AI engine, PandaOmics, the two parties have established a technical foundation for data integration and mechanism analysis. Currently, the research team has integrated 16 public datasets containing 269 samples to conduct gene expression analysis and meta-analysis focused on THP-001. THP-001 is THPharm's core candidate drug, which is currently in global Phase III clinical trials and is intended for the treatment of type 2 diabetes and primary hypertension. After the THP-001 project completes its pilot and establishes relevant analysis processes, both parties plan to further expand this method to THPharm's pipeline in more metabolic disease areas.